Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Jan 6, 2025
- Accession no.
- 0001140361-25-000339
- Filed
- Jan 6, 2025
- Trade date
- Jan 3, 2024-Jan 3, 2025
- Filing delay
- 369 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $47.5K. It was filed 369 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001140361-25-000827 (Jan 10, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | Common Stock | SSaleDisposed | −2,000 | $12.40F2 | −$24,800 | 2,920,467 | Indirect | |
| Jan 3, 2025 | Common Stock | SSaleDisposed | −1,167 | $11.03F3 | −$12,872.01 | 2,919,300 | Indirect | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −833 | $11.85F4 | −$9,871.05 | 2,918,467 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.99 to $12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.73 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.73 to $12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.